SIAG
MTNB icon

Signet Investment Advisory Group’s Matinas BioPharma MTNB Stock Holding History

Signet Investment Advisory Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1
Closed -$1K – 152
2020
Q4 		$1K Buy
+1
New +$695 ﹤0.01% 212

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Signet Investment Advisory Group's MTNB Position: Q1 2021 in Review

Signet Investment Advisory Group sold out of Matinas BioPharma (MTNB) in Q1 2021, closing a stake of 1 share — an estimated $1K sold.

Signet Investment Advisory Group first reported a position in MTNB in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 80 funds tracked by Wall St. Rank hold MTNB as of Q1 2021.

  • Signet Investment Advisory Group reported no remaining Matinas BioPharma position as of Q1 2021 after selling out during the quarter.
  • Signet Investment Advisory Group sold 1 Matinas BioPharma share in Q1 2021, an estimated $1K.
  • Signet Investment Advisory Group first reported a position in Matinas BioPharma in Q4 2020 and held it in 1 quarter.
  • Signet Investment Advisory Group's Matinas BioPharma position peaked at $1K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2021.

Based on Signet Investment Advisory Group's 13F filing for Q1 2021, filed 11 May 2021.